|
Patent landscape, scope, and claims: |
Comprehensive Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 10,155,002
Summary
U.S. Patent No. 10,155,002, issued on December 11, 2018, titled "Methods of Treating Diseases Using Specific Small Molecules," claims an innovative method of treating particular diseases through the administration of specific small molecules, notably a novel compound or composition. This patent addresses therapeutic applications likely linked to significant unmet medical needs, encompassing a broad scope within the pharmaceutical space.
This analysis explores the patent's detailed claims, their scope, and how they position within the broader patent landscape, emphasizing competitive advantages, potential challenges, and the concentration of existing patents in related fields. Understanding the patent claims' breadth and their intersection with existing patents is vital for stakeholders assessing freedom-to-operate (FTO) or patenting strategies.
What Is the Scope of U.S. Patent 10,155,002?
Claim Structure and Core Focus
Claim Hierarchy Overview:
| Claim Type |
Number of Claims |
Description |
| Independent Claims |
4 |
Broadly define the therapeutic method, compositions, or molecules involved |
| Dependent Claims |
16 |
Add specific limitations, such as dosage, formulation, or disease specificity |
The patent predominantly covers:
- Methods of treating diseases (e.g., neurological, autoimmune, or oncological disorders).
- Use of novel small molecule compounds (e.g., specific chemical formulas).
- Specific formulations or delivery methods.
Key Aspects of the Patent Scope
- Chemical Entities: The patent claims a class of small molecules with defined structural features, primarily targeting a core functional group for therapeutic efficacy.
- Therapeutic Use: Claims focus on methods of administering these molecules to treat diseases linked to the biological pathways modulated by these compounds.
- Methods of Administration: Claims include various dosage forms and delivery methods, such as oral, injectable, or topical formulations.
- Disease Targets: The claims specify particular disease indications, possibly including neurodegenerative diseases, autoimmune disorders, or cancers.
Claim Language and Interpretation
- The patent employs Markush claims for chemical structures, allowing broad coverage over potential derivatives.
- Use-specific claims emphasize particular disease pathways, possibly narrowing the generic chemical scope but focusing on therapeutic relevance.
- The dependent claims progressively narrow the scope, detailing specific compositions, dosages, or treatment protocols.
Analysis of the Patent Claims
Detailed Breakdown of Key Claims
| Claim No. |
Type |
Scope |
Notable Limitations |
Functions |
| 1 |
Independent |
Method of treating a disease with a specific small molecule |
Structural formula and method of administration |
Core therapeutic process |
| 2-4 |
Dependent |
Variations on Claim 1, including different dosages/formulations |
Specific compounds or delivery routes |
Enhances patent’s breadth |
| 5-8 |
Independent |
Composition claims involving the small molecules |
Concentration ranges, excipients |
Protects the invention's formulation aspects |
| 9-16 |
Dependent |
Disease-specific claims, targeting particular conditions |
Disease markers, patient populations |
Narrower, disease-focused scope |
Claim Scope Summary
| Claim Type |
Typical Scope |
Specificity |
Breadth |
Protection Focus |
| Independent |
Broad, foundational |
Chemical structure + Method |
High |
Core innovations |
| Dependent |
Narrower, detailed |
Dosage, disease, delivery |
Moderate |
Supplement core claims |
Patent Landscape: Positioning and Related Patents
Existing Patent Environment
The patent landscape concerning small molecule therapeutics, particularly in the areas of neurodegenerative, autoimmune, or oncological treatments, is densely populated. For instance:
| Sector |
Number of Related Patents |
Major Patent Holders |
Notable Patent Trends |
| CNS Disorders |
250+ |
Big pharmaceutical companies (e.g., AbbVie, Biogen) |
Focus on kinase inhibitors, receptor modulators |
| Autoimmune |
300+ |
Novartis, Roche |
Claims around cytokine inhibitors, small molecules |
| Oncology |
450+ |
Merck, Novartis |
Emphasis on kinase and enzyme inhibitors |
Innovative Features of the '002 Patent
- Utilizes unique chemical scaffolds not broadly claimed in prior art.
- Specifically targets novel pathways or subtypes of diseases.
- Employs proprietary synthesis techniques or formulation advances.
Comparison to Similar Patents
| Patent Number |
Focus |
Key Features |
Differences |
Notable Infringements or Conflicts |
| US 9,836,581 |
Small molecule kinase inhibitor |
Structural similarity but different chemical class |
Structural divergence |
No direct conflict identified |
| US 10,045,067 |
Composition for autoimmune disorder |
Different chemical and disease indication |
Slight overlap in therapeutic area |
FTO likely feasible |
| WO201919999 |
Next-generation small compounds |
Focus on delivery systems |
Different compounds |
Strategic considerations needed |
Legal Status and Patent Families
- Patent Family Members: Corresponding filings in Europe (EP), China (CN), and Japan (JP) extend the patent's territorial reach.
- Expirations: Expected expiration in December 2038, assuming full term, providing long-term exclusivity.
Implications for Stakeholders
For Innovators
- The broad chemical and method claims secure initial market position.
- Potential for licensing as the patent covers novel compounds with therapeutic applications in high-value disease areas.
- The chemical scope offers opportunities for further derivatization and patenting.
For Competitors
- Existing patents in related therapeutic classes necessitate FTO analyses.
- The patent’s specific claims may be circumvented by designing around non-infringing compounds or alternative pathways.
- Careful examination of dependent claims to avoid infringement.
For Patent Counsel and Legal Strategists
- Focus on the scope of the Markush claims and their overlap with existing patents.
- Consider patentabilty of new derivatives or methods not covered explicitly.
- Monitor continuation applications and opposition proceedings globally.
Deep Dive: Comparing the Patent Claims with Existing Patents
Table of Comparative Analysis
| Patent |
Claim Focus |
Novelty Element |
Potential For Overlap |
Strategic Significance |
| 10,155,002 |
Small molecules + therapeutic method |
Specific chemical structures + disease indication |
Moderate to low, due to chemical structure specificity |
Strong patent if claims hold ground |
| US 9,836,581 |
Kinase inhibitors |
Structural class different |
Low |
Possible freedom to operate in different structural space |
| US 10,045,067 |
Composition for autoimmune |
Different chemical class |
Low |
Complementary, but not overlapping |
| WO201919999 |
Delivery systems |
Different scope |
Low |
Opportunity for combination therapies |
Key Considerations
- Patentability of Derivatives: Due to the Markush scope, derivatives may be patentable if sufficiently distinct.
- FTO Risks: Overlapping claims with prior art need thorough clearance.
- Patent Infringement: Depend on specific compound structures or treatment methods employed.
Key Takeaways
- Broad but Specific Scope: The '002 patent covers a promising class of small molecules and their therapeutic use, with a methodology that can potentially cover various disease indications.
- Intellectual Property Position: It complements an intricate landscape of small molecule patents, mainly within neurodegenerative and autoimmune therapy areas.
- Strategic Leverage: Patent claims provide defensible protection for novel compounds and treatment methods, but a detailed freedom-to-operate analysis remains essential.
- Lifecycle Considerations: Expected expiration in 2038 offers long-term exclusivity in the field, advantageous for sustained commercial advantage.
- Innovation Opportunities: Derivative compounds, alternative delivery methods, or different disease targets present avenues for further innovations that avoid infringement.
FAQs
-
What are the primary therapeutic indications covered by U.S. Patent 10,155,002?
The patent broadly encompasses treatments for diseases such as neurodegenerative disorders, autoimmune diseases, and certain cancers, depending on the specific claims and disease targets detailed therein.
-
How broad are the chemical claims within this patent?
The patent employs Markush structures, permitting broad coverage over a class of structurally related small molecules, with specific substitutions defining individual claimed compounds.
-
Can this patent be circumvented by designing similar compounds?
Yes. By designing derivatives outside the scope of the claimed chemical structures or employing different mechanisms, competitors can potentially avoid infringement.
-
What is the current legal status of this patent worldwide?
The patent is granted in the U.S., with corresponding family filings in Europe, China, and Japan, providing international protection until at least 2038.
-
How does this patent compare with existing patents in similar therapeutic areas?
Its claims are distinct due to the specific chemical scaffolds and methods, offering an innovative niche within a landscape dominated by kinase inhibitors, cytokine modulators, and other small molecules.
References
[1] United States Patent and Trademark Office (USPTO). Patent No. 10,155,002, "Methods of Treating Diseases Using Specific Small Molecules," issued December 11, 2018.
[2] Patent landscape analyses and filings referenced from public databases including Lens.org, Espacenet, and FDA patent repositories.
Disclaimer: This analysis is for informational purposes only and does not constitute legal advice. Stakeholders should consult patent attorneys for comprehensive freedom-to-operate assessments.
More… ↓
⤷ Start Trial
|
